Krystal Biotech (KRYS) Liabilities and Shareholders Equity (2016 - 2026)

Krystal Biotech has disclosed Liabilities and Shareholders Equity across 11 years of filings, most recently posting $1.4 billion for Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $1.4 billion, up 30.02% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.1 billion (up 26.77% YoY), and the FY2025 annual result was $1.3 billion, up 26.33% from the prior year.
• Liabilities and Shareholders Equity came in at $1.4 billion for Q1 2026 at Krystal Biotech, up from $1.3 billion in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $1.4 billion in Q1 2026 to a low of $531.8 million in Q1 2023.
• The 5-year median for Liabilities and Shareholders Equity is $853.3 million (2024), against an average of $892.4 million.
• Across the five-year window, Liabilities and Shareholders Equity decreased 13.78% in 2023 and surged 60.44% in 2024, its largest moves.
• Krystal Biotech's Liabilities and Shareholders Equity stood at $558.4 million in 2022, then surged by 46.54% to $818.4 million in 2023, then rose by 29.02% to $1.1 billion in 2024, then climbed by 26.33% to $1.3 billion in 2025, then rose by 4.74% to $1.4 billion in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $1.4 billion (Q1 2026), $1.3 billion (Q4 2025), and $1.2 billion (Q3 2025), per Business Quant data.